Genital herpes

This early-stage trial tested whether a new herpes vaccine called HSV529 is safe for people. Researchers gave the vaccine or a placebo to 69 healthy adults aged 18 to 40, some of whom had herpes and some who did not. Participants received three shots over six months and were moni…

This study tested an experimental mRNA vaccine (mRNA-1608) in 303 healthy adults aged 18 to 55 with recurrent genital herpes caused by HSV-2. The goal was to see if the vaccine is safe and can reduce the number of outbreaks. Participants received different doses of the vaccine or…

This early-stage study tested a new drug called ABI-5366 in 115 people to see if it is safe and how the body processes it. Part A involved healthy volunteers receiving a single dose, while Part B included people with recurrent genital herpes who received multiple doses. The goal …

This early study tests an experimental drug called ABI-1179 in healthy volunteers and people with recurrent genital herpes caused by HSV-2. The main goal is to check safety and how the body processes the drug. Researchers will give single or multiple doses and monitor for side ef…

This study tested an experimental immunotherapy for herpes simplex virus (HSV) in 505 people. In the first part, healthy adults aged 18-40 received different vaccine-like formulations to check safety. In the second part, adults aged 18-60 with recurrent genital herpes got the tre…